"According to a 2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75 billion by 2015; Amarantus is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinson's drug market. There are currently no diagnostic tests available for Parkinson's disease, thus making Amarantus' test a first of its kind product capable of gaining a market leading position."
Market Data 
Markets 
AI
